Hepatotoxicity and pharmacokinetics of cisplatin in combination therapy with a traditional Chinese medicine compound of Zengmian Yiliu granules in ICR mice and SKOV-3-bearing nude mice

BMC Complementary and Alternative Medicine

Chang-hong Wang³  Cong Qi²  Wen-bin Zhou¹  Hai Wei¹  Li-li Ji³  Hong Yang²  Lin Qian²  Can Gong⁴ 

[1] Research Center for Traditional Chinese Medicine and Systems Biology, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Zhangjiang Hi-Tech Park, Shanghai 201203, People’s Republic of China;Department of Gynaecology, Shanghai Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine, 528 Zhang Heng Road, Zhangjiang Hi-Tech Park, Shanghai 201203, People’s Republic of China;The Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, The Ministry of Education (MOE) Key Laboratory for Standardization of Chinese Medicines and Shanghai Key Laboratory of TCM Complex Prescription, 1200 Cailun Road, Zhangjiang Hi-Tech Park, Shanghai 201203, People’s Republic of China;School and Chemical and Environmental Engineering, Shanghai Institute of Techanology, 100 Haiquan Road, Shanghai 201418, Fengxian, People’s Republic of China

关键词: Zengmian Yiliu granule;    Pharmacokinetics;    Hepatotoxicity;    Cisplatin;   

Others  :  1222532
DOI  :  10.1186/s12906-015-0799-9

 received in 2015-04-02, accepted in 2015-08-03,  发布年份 2015

【 摘 要 】

Background

Cisplatin (CDDP) is a highly effective chemotherapeutic agent used for therapy of many tumors and has been limited by its toxicity. Zengmian Yiliu granule (ZMYL), a compound preparation of traditional Chinese medicines, has been used in clinic as a complementary and alternative medicine for attenuating CDDP-induced toxicities and enhancing the tumor therapeutic effect of CDDP. The aim of the present study is to investigate hepaprotective effect of ZMYL against CDDP-induced hepatotoxicity. Further, the pharmacokinetic characteristics of CDDP in SKOV-3-bearing nude mice were observed.

Methods

The ICR mice were dosed orally with ZMYL for 7 days and then CDDP was injected intraperitoneally at a dose of 45 mg/kg body weight. The serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured to evaluate the liver function. The total glutathione (T-GSH), reduced glutathione (GSH) and glutathione S-transferase (GST) levels were determined to evaluate the oxidant damage in liver homogenates. Tissue pathological change in liver was conducted by light microscopy analysis. The pharmacokinetic and tissue distribution of free and total platinum (Pt) after dosing of CDDP alone and combination with ZMYL were determined in SKOV-3-bearing nude mice by ICP-MS.

Results

Oral administration of ZMYL prior to the CDDP treatment could prevent the CDDP-induced in lifting of ALT and AST, reduction of T-GSH, R-GSH and GST, and some histopathological alterations in ICR mice. Some differences in pharmacokinetic parameters between the two groups have been observed in higher CL and decreased MRT of free platinum (Pt) in plasma and total Pt in spleen in CDDP co-administration with ZMYL group. It indicated CDDP was cleared more quickly from blood and spleen, and could reduce the accumulation and toxic possibility of CDDP in combination with ZMYL.

Conclusions

ZMYL could be used as a beneficial supplement, which could attenuate CDDP-induced hepatotoxicity during CDDP chemotherapy and did not disturb the pharmacokinetics fate of CDDP significantly.

【 授权许可】

   
2015 Gong et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Gelderblom H, Loos WJ, Verweij J, van der Burg MEL, de Jonge MJA, Brouwer E, Nooter K, Stoter G, Sparreboom A. Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies. Eur J Cancer. 2002; 38(1):205-213.
• [2]Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol. 1985; 249(4):490-496.
• [3]Chirino YI, Hernández-Pando R, Pedraza-Chaverrí J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol. 2004; 4(1):20. BioMed Central Full Text
• [4]Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, Loo TL. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol. 1982; 10(1):51-54.
• [5]Kim YK, Jung JS, Lee SH, Kim YW. Effects of antioxidants and Ca 2+ in cisplatin-induced cell injury in rabbit renal cortical slices. Toxicol Appl Pharmcol. 1997; 146(2):261-269.
• [6]Somani SM, Husain K, Whitworth C, Trammell GL, Malafa M, Rybak LP. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol Toxicol. 2000; 86(5):234-241.
• [7]Mora LO, Antunes LM, Francescato HD, Bianchi ML. The effects of oral glutamine on cisplatin-induced nephrotoxicity in rats. Pharmacol Res. 2003; 47(6):517-522.
• [8]Giridharan VV, Thandavarayan RA, Bhilwade HN, Ko KM, Watanabe K, Konishi T. Schisandrin B, attenuates cisplatin-induced oxidative stress, genotoxicity and neurotoxicity through modulating NF-κB pathway in mice. Free Radical Res. 2012; 46(1):50-60.
• [9]Sahu BD, Rentam KK, Putcha UK, Kuncha M, Vegi GM, Sistla R. Carnosic acid attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Food Chem Toxicol. 2011; 49(12):3090-3097.
• [10]Rodrigues MA, Rodrigues JL, Martins NM, Barbosa F, Curti C, Santos NA, Santos AC. Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats. Mitochondrion. 2010; 10(1):46-53.
• [11]Park HR, Ju EJ, Jo SK, Jung U, Kim SH, Yee ST. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009; 9(1):85-95. BioMed Central Full Text
• [12]Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer FH, Pinedo HM, van der Vijgh WJ. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer. 2002; 38(8):1148-1156.
• [13]Suddek GM. Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals. Cancer Chem Pharmacol. 2011; 67(5):1035-1044.
• [14]Dwivedi C, Agrawal P, Natarajan K, Sharma H. Antioxidant and protective effects of Amrit Nectar tablets on adriamycin-and cisplatin-induced toxicities. J Altern Complem Med. 2005; 11(1):143-148.
• [15]Zhang QH, Hu XX, Qi C, Li JX. Experimental study on regulating effects of Zengmian Yiliu granule on immunosuppression and myelosuppression following large-dose chemotherapy in ovarian carcinoma. Shanghai J Trad Chinese Med. 2003; 45(1):71-74.
• [16]Hu XX, Zhang QH, Qi C, Li JX. Anti-angiogenic effects of Zengmian Yiliu granule on ovarian carcinoma xenograft. Chinese J Integr Trad Western Med. 2012; 32(7):970-974.
• [17]Li JX, Zhang QH, Hu XX, Qi C. Effects of Zengmian Yiliu decoction on expression of resistance related genes HIF-1, Glut1, MDR1, P-gp in nude mice with cisplatin-resistant ovarian cancer. Shanghai J Trad Chinese Med. 2012; 46(1):61-64.
• [18]Zhang QH, Gong C, Yang H, Wei H, Zhou WB, Qi C, Wang CH. Pharmacokinetics of cisplatin in the absence or presence of ZengmianYiliu granules (a traditional Chinese medicine compound) in rats determined via ICP-MS: An investigation on drug–herbs interactions. Pharmaceut Biol. 2015; 53(2):159-166.
• [19]O’Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, Brueggen J, Bruelisauer A, Gschwind HP, Allegrini PR, Lane HA. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol. 2010; 65(4):625-639.
• [20]Deng YX, Shi QZ, Chen B, Zhang XJ, Liu SZ, Qiu XM. Comparative pharmacokinetics of baicalin in normal and the type 2 diabetic rats after oral administration of the Radix scutellariae extract. Fitoterapia. 2012; 83(8):1435-1442.
• [21]Yang J, Lv F, Chen XQ, Cui WX, Chen LH, Wen XD, Wang Q. Pharmacokinetic study of major bioactive components in rats after oral administration of extract of Ilex hainanensis by high-performance liquid chromatography/electrospray ionization mass spectrometry. J Pharmaceut Biomed Anal. 2013; 77(4):21-28.
• [22]Liu J, Liu Y, Habeebu SS, Klaassen CD. Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol Appl Pharmcol. 1998; 149(1):24-31.
• [23]Johnsson A, Björk H, Schütz A, Skärby T. Sample handling for determination of free platinum in blood after cisplatin exposure. Cancer Chemother Pharmacol. 1997; 41(3):248-251.
• [24]Lu Y, Cederbaum AI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol Science. 2006; 89(2):515-523.
• [25]Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Stahl E. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol. 1995; 37(1-2):23-31.
• [26]Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. J Chem Educat. 2006; 83(5):728-734.
• [27]Lee CK, Park KK, Hwang JK, Lee SK, Chung WY. The extract of Prunus persica Flesh (PPFE) attenuates chemotherapy-induced hepatotoxicity in mice. Phytother Res. 2008; 22(2):223-227.
• [28]Gaona-Gaona L, Molina-Jijón E, Tapia E, Zazueta C, Hernández-Pando R, Calderón-Oliver M, Zarco-Márquez G, Pinzón E, Pedraza-Chaverri J. Protective effect of sulforaphane pretreatment against cisplatin-induced liver and mitochondrial oxidant damage in rats. Toxicology. 2011; 286(1):20-27.
• [29]Cayır K, Karadeniz A, Simşek N, Yıldırım S, Karakuş E, Kara A, Akkoyun HT, Sengül E. Pomegranate seed extract attenuates chemotherapy-Induced acute nephrotoxicity and hepatotoxicity in rats. J Med Food. 2011; 14(11):1254-1256.
• [30]Kart A, Cigremis Y, Karaman M, Ozen H. Caffeic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit. Exper Toxicol Pathol. 2010; 62(1):45-52.
• [31]Liao YJ, Lu XQ, Lu CW. Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacol Res. 2008; 57(2):125-131.
• [32]Zhao D, Zhang Y, Xu C, Dong C, Lin H, Zhang L, Li C, Ren S, Wang X, Yang S, Han D, Chen X. Pharmacokinetics, tissue distribution, and plasma protein binding study of platinum originating from dicycloplatin, a novel antitumor supramolecule, in rats and dogs by ICP-MS. Biol Trace Elem Res. 2012; 148(2):203-208.
• [33]Gong Z, Chen Y, Zhang R, Wang Y, Guo Y, Yang Q, Zhang H, Dong Y, Weng X, Gao S, Zhu X. Pharmacokinetic comparison of berberine in rat plasma after oral administration of berberine hydrochloride in normal and post inflammation irritable bowel syndrome rats. Inter J Mol Sci. 2014; 15(1):456-467.
• [34]Han Q, Pan GL, Zhang YW. Pharmacokinetics study of lansoprazole between gastric ulcer and normal rabbits. Pharmaceut Clinic Res. 2011; 19(1):22-25.